

Table S1Multivariate analyses of overall survival in EGFR-positivepatients with gradual progression after TKI failure.

Parameter	Total				19 Del				L858R			
	N	HR	95%CI	P-value	N	HR	95%CI	P-value	N	HR	95%CI	P-value
Age (years)												
<60y	40				27				13			
≥60y	31	1.126	0.648-1.955	0.674	11	1.440	0.640-3.239	0.378	20	1.002	0.456-2.203	0.996
Smoking status												
Never	57				29				28			
Smoker	14	1.195	0.582-2.456	0.627	9	0.799	0.292-2.190	0.663	5	1.917	0.538-6.827	0.315
Line of TKI												
1st	31				14				17			
≥2nd	40	1.011	0.590-1.732	0.969	24	0.719	0.322-1.606	0.421	16	1.045	0.470-2.325	0.913
EGFR mutation												
19 Del	38											
L858R	33	1.095	0.617-1.943	0.758								
Subsequent treatment												
BSC	15				5				10			
Chemo	41	0.414	0.214-0.801	0.009	23	0.454	0.158-1.307	0.143	18	0.565	0.223-1.428	0.228
Pre TKI	15	0.176	0.069-0.449	<0.001	10	0.335	0.092-1.370	0.133	5	0.121	0.025-0.589	0.009

Abbreviations:19 Del, exon 19 deletion; L858R, exon 21 L858R mutation; EGFR, epidermal growth factor receptor; Pre TKI,previous tyrosine kinase inhibitor; BSC, best supportive care; Chemo, chemotherapy; HR, hazard ratio; CI, confidence interval.

Table S2 Multivariate analyses of overall survival in EGFR-positive patients with dramatic progression after TKI failure.

Parameter	Total				19 Del				L858R			
	N	HR	95%CI	P-value	N	HR	95%CI	P-value	N	HR	95%CI	P-value
Age (years)												
<60y	46				19				27			
≥60y	23	0.847	0.483-1.486	0.563	15	1.690	0.784-3.643	0.181	8	0.441	0.178-1.092	0.077
Smoking status												
Never	54				26				28			
Smoker	15	1.496	0.799-2.800	0.208	8	0.846	0.332-2.158	0.727	7	1.371	0.547-3.440	0.501
Line of TKI												
1st	27				13				14			
≥2nd	42	0.596	0.346-1.026	0.062	21	0.762	0.343-1.693	0.504	21	0.428	0.191-0.959	0.039
EGFR mutation												
19 Del	34											
L858R	35	1.108	0.640-1.918	0.715								
Subsequent treatment												
BSC	44				6				11			
Chemo	8	0.606	0.315-1.164	0.133	25	0.251	0.079-0.797	0.019	19	0.861	0.389-1.908	0.713
Pre TKI	17	0.469	0.174-1.261	0.133	3	1.987	0.442-8.940	0.371	5	0.285	0.072-1.127	0.074

Abbreviations: 19 Del, exon 19 deletion; L858R, exon 21 L858R mutation; EGFR, epidermal growth factor receptor; Pre TKI, previous tyrosine kinase inhibitor;

BSC, best supportive care; Chemo, chemotherapy; HR, hazard ratio; CI, confidence interval.